Navigation Links
The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022
Date:12/12/2013

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will decrease from $21.4 billion in 2012 to $18.3 billion in 2017, but will recover to $21.6 billion by 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"The sales pattern in the total chronic pain market is attributable to the loss of market exclusivity for key chronic pain therapies, including controlled-release oxycodone (Purdue Pharma/Mundipharma/Napp Pharmaceuticals' OxyContin), over the next five years," said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. "Market contraction in the first half of the forecast period will be followed by a growth in sales from 2017 through 2022, driven by the launches of a number of emerging therapies."

The Pharmacor report entitled Chronic Pain also finds that the pipeline of therapies in clinical development for chronic pain conditions continues to be composed largely of reformulations of existing molecules—however, agents with novel mechanisms of action, such as subtype-selective sodium channel blockers and monoclonal antibodies against nerve growth factor (NGF), have made recent and notable developmental advances. Overcoming delays due to safety concerns, anti-NGF therapies such as Eli Lilly/Pfizer's tanezumab and Johnson & Johnson/Takeda's fulranumab are forecast to garner significant sales from use in patients with severe, treatment-refractory osteoarthritis pain or chronic low back pain. This class will comprise 19 percent of major-market sales for chronic pain therapies by 2022.

The report also highlights that effective analgesics with lower risk of tolerance and abuse remains a key area of unmet need in this market. Now that the FDA has established a regulatory path for abuse-deterrent, long-acting and extended-release opioids, several abuse-deterrent products from developers including Pfizer, Teva and Purdue are expected to launch in the United States over the next five years. In 2022, sales of abuse-deterrent opioid formulations attributed to chronic pain treatment will exceed $1 billion across the multiple chronic pain indications covered in the report.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
2. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
3. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
4. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
5. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
6. Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. West to Co-present Research Findings on Understanding the Patient Journey through the Phases of a Chronic Disease
8. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
9. Is Chronic Pain Keeping You Awake? Help Is On the Way
10. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
11. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):